Avedro (maker of the FDA approved corneal cross-linking system) announced the one year results from their phase 3 clinical trial.
At the 12 month follow up, they found:
- Steep K values decreased by 1.6D.
- Visual acuity improved by 5.5 letters.
- Adverse events were reported in 5 eyes (out of 205). They were persistent corneal haze in 2 eyes, corneal scar in 1 eye, endothelial folds in 1 eye, and irregular corneal epithelium in 1 eye.
The authors state, “this trial demonstrated the efficacy and safety of CXL for the treatment of progressive keratoconus”.